Minolira Extended Release
NDC Package 71403-101-30
Package Information
Minolira Extended Release is mINOLIRA is indicated to treat the inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Marketed by Epi Health, Inc, this product is identified by NDC 71403-101 and is authorized under FDA application NDA209269.
Identification & Billing
- RxCUI: 1013659 - minocycline HCl 105 MG 24HR Extended Release Oral Tablet
- RxCUI: 1013659 - 24 HR minocycline 105 MG Extended Release Oral Tablet
- RxCUI: 1013659 - minocycline 105 MG (26.25 MG Immediate Release Beads / 78.75 MG Extended Release Beads) 24 HR Extended Release Oral Tablet
- RxCUI: 1013659 - minocycline 105 MG (as minocycline HCl 113.4 MG) 24 HR Extended Release Oral Tablet
- RxCUI: 1013659 - minocycline 105 MG 24 HR Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71403 - Epi Health, Inc
- 71403-101 - Minolira Extended Release
- 71403-101-30 - 1 BOTTLE in 1 CARTON / 30 TABLET in 1 BOTTLE
- 71403-101 - Minolira Extended Release
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (71403-101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71403-101-30 identifies a specific commercial package of 1 bottle in 1 carton / 30 tablet in 1 bottle of Minolira Extended Release, labeled by Epi Health, Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Epi Health, Inc on March 15, 2019. The current certification is valid through December 31, 2023.
How is this Epi Health, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71403010130. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.